大剂量分次立体定向放疗治疗脑转移瘤:CyberKnife 安装后 8 年经验
法国 Léon Bérard 癌症中心回顾性分析 389 例患者共 400 个脑转移瘤,接受单纯大剂量分次立体定向放疗(HFSRT)或手术后 HFSRT,比较 27 Gy(3×9 Gy)、30 Gy(5×6 Gy)、35 Gy(5×7 Gy)三种方案。不同剂量分次方案间无统计学差异;多因素分析显示手术(p=0.049)与病灶<2.5 cm(p=0.01)为局部控制独立改善因素,手术+HFSRT 组 12 个月局部控制率 87.02% 对单纯 HFSRT 组 73.53%,总生存率 61.43% 对 50.13%(p<0.0085)。
要点
- 三种 HFSRT 剂量分次方案间局部控制无统计学差异
- 手术与病灶<2.5 cm 是局部控制的独立改善因素
- 手术+HFSRT 组 12 个月 OS 61.43% 优于单纯 HFSRT 组 50.13%(p<0.0085)
核心结论
- HFSRT 是有效且耐受性良好的治疗,最佳剂量分次方案仍难以确定;较小病灶与手术与局部控制相关,结果支持对>2.5 cm 且预后较差的脑转移瘤行手术。
研究设计与样本
- 法国 Léon Bérard 癌症中心回顾性研究,纳入 18 岁以上、组织学证实原发肿瘤的脑转移患者,接受单纯 HFSRT 或手术后 HFSRT。
- 比较三种剂量分次方案:27 Gy(3×9 Gy)、30 Gy(5×6 Gy)、35 Gy(5×7 Gy),处方于 80% 等剂量线。
- 共分析 389 例患者、400 个脑转移瘤,均有规律 MRI 随访;主要终点为局部控制,次要终点为总生存与放射性坏死率。
主要发现
- 不同剂量分次方案之间无统计学差异。
- 多因素分析中手术(p=0.049)与病灶<2.5 cm(p=0.01)是改善局部控制的独立因素。
- 手术+HFSRT 组 12 个月局部控制率 87.02%,单纯 HFSRT 组 12 个月为 73.53%。
- 手术+HFSRT 组 12 个月总生存率 61.43%,单纯 HFSRT 组 12 个月为 50.13%(p<0.0085)。
- 既往手术(OR=1.86;p=0.0028)、性别(OR=1.4;p=0.0139)、原发肿瘤控制(OR=0.671,p=0.0069)与 KPS<70(OR=0.769,p=0.0094)为总生存的独立预测因素;放射性坏死率为 5%,相关患者均有症状。
关键数值与推荐
- 三种 HFSRT 方案:27 Gy(3×9 Gy)、30 Gy(5×6 Gy)、35 Gy(5×7 Gy),均处方于 80% 等剂量线。
- 局部控制独立因素:手术 p=0.049,病灶<2.5 cm p=0.01。
- 总生存独立预测因素:既往手术 OR=1.86(p=0.0028)、性别 OR=1.4(p=0.0139)、原发肿瘤控制 OR=0.671(p=0.0069)、KPS<70 OR=0.769(p=0.0094)。
- 放射性坏死率 5%,均为有症状患者。
临床怎么用
- 对较大(>2.5 cm)或邻近脑干、视交叉、视神经、海马的脑转移瘤可考虑 HFSRT。
- 较大且预后较差的脑转移瘤可考虑手术联合 HFSRT 以改善局部控制与生存。
- 剂量分次方案选择尚无最优证据,需结合多学科委员会讨论并期待前瞻性研究验证。
局限性
- 为单中心回顾性研究,结果需前瞻性研究验证。
- 最佳剂量分次方案仍难以确定,三种方案间无统计学差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was to assess factors influencing BM local control after HFSRT. Then the effect of surgery plus HFSRT was compared with exclusive HFSRT on oncologic outcomes, including overall survival. MATERIALS AND METHODS: Retrospective study conducted in Léon Bérard Cancer Center, included patients over 18 years-old with BM, secondary to a tumor proven by histology and treated by HFSRT alone or after surgery. Three different dose-fractionation schedules were compared: 27 Gy (3 × 9 Gy), 30 Gy (5 × 6 Gy) and 35 Gy (5 × 7 Gy), prescribed on isodose 80%. Primary endpoint were local control (LC). Secondary endpoints were overall survival (OS) and radionecrosis (RN) rate. RESULTS: A total of 389 patients and 400 BM with regular MRI follow-up were analyzed. There was no statistical difference between the different dose-fractionations. On multivariate analysis, surgery (p = 0.049) and size (< 2.5 cm) (p = 0.01) were independent factors improving LC. The 12 months LC was 87.02% in the group Surgery plus HFSRT group vs 73.53% at 12 months in the group HFSRT. OS was 61.43% at 12 months in the group Surgery plus HFSRT group vs 50.13% at 12 months in the group HFSRT (p < 0.0085). Prior surgery (OR = 1.86; p = 0.0028) and sex (OR = 1.4; p = 0.0139) control of primary tumor (OR = 0.671, p = 0.0069) and KPS < 70 (OR = 0.769, p = 0.0094) were independently predictive of OS. The RN rate was 5% and all patients concerned were symptomatic. CONCLUSIONS: This study suggests that HFSRT is an efficient and well-tolerated treatment. The optimal dose-fractionation remains difficult to determine. Smaller size and surgery are correlated to LC. These results evidence the importance of surgery for larger BM (> 2.5 cm) with a poorer prognosis. Multidisciplinary committees and prospective studies are necessary to validate these observations.
引用
- Mengue L, Bertaut A, Ngo Mbus L, et al. Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation. Radiat Oncol. 2020. PMID: 32303236. doi:10.1186/s13014-020-01517-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。